Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

The Office of Mayo Clinic Experience: A Strategy to Continuously Improve Patient Experience
Howell, Thomas G., Leighton, Jonathan A. , Poole, Kenneth , Gasparini, Robin N., Welch, Thomas, Hart, Lacey, Kilen, Andrea L., Stevens, Sheila K., Wilshusen, Laurie , Howell, Thomas G.

Mayo Clinic

NEJM Catalyst | August 17, 2022 | Volume: 3 | Issue: 9 | Pages: No page available

10.1056/cat.21.0476 Get It

Corticosteroids for patients with vestibular neuritis: An evidence synthesis for guidelines for reasonable and appropriate care in the emergency department
Silva, Lucas Oliveira J. e , Khoujah, Danya , Naples, James G. , Edlow, Jonathan A. , Gerberi, Dana , Carpenter, Christopher R. , Bellolio, Fernanda , Oliveira J E Silva, Lucas , Bellolio, M Fernanda , Carpenter, Christopher R , Khoujah, Danya

Mayo Clinic

Academic Emergency Medicine | August 17, 2022 | Volume: 30 | Issue: 5 | Pages: 531-540

10.1111/acem.14583 | PMID 35975654 Get It

AbstractBackgroundA short course of corticosteroids is among the management strategies considered by specialists for the treatment of vestibular neuritis (VN). We conducted an umbrella review (systematic review of systematic reviews) to summarize the evidence of corticosteroids use for the treatment of VN.MethodsWe included systematic reviews of randomized controlled trials (RCTs) and observational studies that evaluated the effects of corticosteroids compared to placebo or usual care in adult patients with acute VN. Titles, abstracts, and full texts were screened in duplicate. The quality of reviews was assessed with the A MeaSurement Tool to Assess systematic Reviews (AMSTAR‐2) tool. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment was used to rate certainty of evidence. No meta‐analysis was performed.ResultsFrom 149 titles, five systematic reviews were selected for quality assessment, and two reviews were of higher methodological quality and were included. These two reviews included 12 individual studies and 660 patients with VN. In a meta‐analysis of two RCTs including a total of 50 patients, the use of corticosteroids (compared to placebo) was associated with higher complete caloric recovery (risk ratio 2.81, 95% confidence interval [CI] 1.32 to 6.00, low certainty). It is very uncertain whether this translates into clinical improvement as shown by the imprecise effect estimates for outcomes such as patient‐reported vertigo or patient‐reported dizziness disability. There was a wide CI for the outcome of dizziness handicap score (one study, 30 patients, 20.9 points in corticosteroids group vs. 15.8 points in placebo, mean difference +5.1, 95% CI −8.09 to +18.29, very low certainty). Higher rates of minor adverse effects for those receiving corticosteroids were reported, but the certainty in this evidence was very low.ConclusionsThere is limited evidence to support the use of corticosteroids for the treatment of VN in the emergency department.
Cost-Effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy in Atrial Fibrillation: The CABANA Randomized Clinical Trial
Chew, Derek S. , Li, Yanhong , Cowper, Patricia A., Anstrom, Kevin J. , Piccini, Jonathan P. , Poole, Jeanne E. , Monahan, Kristi H. , Davidson‐Ray, Linda , Bahnson, Tristram D. , Al‐Khalidi, Hussein R. , Lee, Kerry L. , Packer, Douglas L. , Investigators, for the CABANA, Li, Yanhong , Monahan, Kristi H , Bahnson, Tristram D , Al-Khalidi, Hussein R , Packer, Douglas L , Mark, Daniel B , Daniels, Melanie R. , Mark, Daniel B. , Investigators, for the CABANA

Mayo Clinic

Circulation | August 15, 2022 | Volume: 146 | Issue: 7 | Pages: 535-547

10.1161/circulationaha.122.058575 | PMID 35726631 Get It

Background: In the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation), catheter ablation did not significantly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest compared with drug therapy by intention-to-treat, but did improve the quality of life and freedom from atrial fibrillation recurrence. In the heart failure subgroup, ablation improved both survival and quality of life. Cost-effectiveness was a prespecified CABANA secondary end point. Methods: Medical resource use data were collected for all CABANA patients (N=2204). Costs for hospital-based care were assigned using prospectively collected bills from US patients (n=1171); physician and medication costs were assigned using the Medicare Fee Schedule and National Average Drug Acquisition Costs, respectively. Extrapolated life expectancies were estimated using age-based survival models. Quality-of-life adjustments were based on EQ-5D–based utilities measured during the trial. The primary outcome was the incremental cost-effectiveness ratio, comparing ablation with drug therapy on the basis of intention-to-treat, and assessed from the US health care sector perspective. Results: Costs in the first 3 months averaged $20 794±SD 1069 higher with ablation compared with drug therapy. The cumulative within-trial 5-year cost difference was $19 245 (95% CI, $11 360–$27 170) and the lifetime mean cost difference was $15 516 (95% CI, –$2963 to $35,512) higher with ablation than with drug therapy. The drug therapy arm accrued an average of 12.5 life-years (LYs) and 10.7 quality-adjusted life-years (QALYs). For the ablation arm, the corresponding estimates were 12.6 LYs and 11.0 QALYs. The incremental cost-effectiveness ratio was $57 893 per QALY gained, with 75% of bootstrap replications yielding an incremental cost-effectiveness ratio < $100 000 per QALY gained. With no quality-of-life/utility adjustments, the incremental cost-effectiveness ratio was $183 318 per LY gained. Conclusions: Catheter ablation of atrial fibrillation was economically attractive compared with drug therapy in the CABANA Trial overall at present benchmarks for health care value in the United States on the basis of projected incremental QALYs but not LYs alone.
Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross‐Sectional Tau Positron Emission Tomography
Josephs, Keith A. , Tosakulwong, Nirubol , Gatto, Rodolfo G. , Weigand, Stephen D. , Ali, Farwa , Graff‐Radford, Jonathan , Savica, Rodolfo , Schwarz, Christopher G. , Kantarci, Kejal , Fields, Julie A. , Reichard, Ross R., Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Graff-Radford, Jonathan , Savica, Rodolfo , Schwarz, Christopher G , Kantarci, Kejal , Dickson, Dennis W , Petersen, Ronald C , Whitwell, Jennifer , Whitwell, Jennifer L , Botha, Hugo , Machulda, Mary M. , Senjem, Matthew L. , Boeve, Bradley F. , Jones, David T. , Ramanan, Vijay K. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Annals of Neurology | August 15, 2022 | Volume: 92 | Issue: 6 | Pages: 1016-1029

10.1002/ana.26479 | PMID 36054427 Get It

ObjectiveThis study was undertaken to assess cross‐sectional and longitudinal [18F]‐flortaucipir positron emission tomography (PET) uptake in pathologically confirmed frontotemporal lobar degeneration (FTLD) and to compare FTLD to cases with high and low levels of Alzheimer disease (AD) neuropathologic changes (ADNC).MethodsOne hundred forty‐three participants who had completed at least one flortaucipir PET and had autopsy‐confirmed FTLD (n = 52) or high (n = 58) or low ADNC (n = 33) based on Braak neurofibrillary tangle stages 0–IV versus V–VI were included. Flortaucipir standard uptake value ratios (SUVRs) were calculated for 9 regions of interest (ROIs): an FTLD meta‐ROI, midbrain, globus pallidum, an AD meta‐ROI, entorhinal, inferior temporal, orbitofrontal, precentral, and medial parietal. Linear mixed effects models were used to compare mean baseline SUVRs and annual rate of change in SUVR by group. Sensitivity and specificity to distinguish FTLD from high and low ADNC were calculated.ResultsBaseline uptake in the FTLD meta‐ROI, midbrain, and globus pallidus was greater in FTLD than high and low ADNC. No region showed a greater rate of flortaucipir accumulation in FTLD. Baseline uptake in the AD‐related regions and orbitofrontal and precentral cortices was greater in high ADNC, and all showed greater rates of accumulation compared to FTLD. Baseline differences were superior to longitudinal rates in differentiating FTLD from high and low ADNC. A simple baseline metric of midbrain/inferior temporal ratio of flortaucipir uptake provided good to excellent differentiation between FTLD and high and low ADNC (sensitivities/specificities = 94%/95% and 71%/70%).InterpretationThere are cross‐sectional and longitudinal differences in flortaucipir uptake between FTLD and high and low ADNC. However, optimum differentiation between FTLD and ADNC was achieved with baseline uptake rather than longitudinal rates. ANN NEUROL 2022;92:1016–1029
Historical Changes in Weight Classes and the Influence of NAFLD Prevalence: A Population Analysis of 34,486 Individuals
Nah, Benjamin , Tan, Caitlyn , Aggarwal, Manik , Zeng, Rebecca Wenling , Xiao, Jieling , Tan, Eunice Xiang‐Xuan, Ren, Yi Ping , Chee, Douglas , Neo, Jonathan W. H., Chew, Nicholas , Tseng, Michael T. , Siddiqui, Mohammad Shadab , Dan, Yock Young , Tan, Eunice X. , Ng, Cheng Han , Tan, Caitlyn , Aggarwal, Manik , Chew, Nicholas W S , Tseng, Michael , Ng, Cheng Han , Chan, Kai En , Chin, Yip Han , Tan, Eunice Xiang Xuan , Neo, Jonathan, Sanyal, Arun J. , Muthiah, Mark D

Mayo Clinic

International Journal of Environmental Research and Public Health | August 11, 2022 | Volume: 19 | Issue: 16 | Pages: 9935

10.3390/ijerph19169935 | PMID 36011567 Get It

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease globally in tandem with the growing obesity epidemic. However, there is a lack of data on the relationship between historical weight changes 10 years ago and at present on NAFLD prevalence at the population level. Therefore, we sought to evaluate the relationship between weight classes and the prevalence of NAFLD. Methods: Data were used from the United States National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. Univariate and multivariate general linear model analyses were used to obtain risk ratio (RR) estimations of NAFLD events. Results: In total, 34,486 individuals were analysed, with those who were lean at both time points as the control group. Overweight (RR: 14.73, 95%CI: 11.94 to 18.18, p < 0.01) or obese (RR: 31.51, 95%CI: 25.30 to 39.25, p < 0.01) individuals at both timepoints were more likely to develop NAFLD. Residual risk exists where previously obese individuals became overweight (RR: 14.72, 95%CI: 12.36 to 17.52, p < 0.01) or lean (RR: 2.46, 95%CI: 1.40 to 4.31, p = 0.02), and previously overweight individuals who became lean (RR 2.24, 95%CI 1.42 to 3.54, p = 0.01) had persistent elevated risk of developing NAFLD despite weight regression. Sensitivity analysis identified that a higher proportion of individuals with regression in weight class were diabetics and Mexican Americans, while fewer African Americans saw weight-class regression. Conclusions: Residual risk exists in patients who lost weight despite the smaller magnitude of effect, and targeted weight reductions should still be used to mitigate the risk of NAFLD at the population level.
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Bauer, Sebastian , Jones, Robin L. , Blay, Jean‐Yves , Gelderblom, Hans , George, Suzanne , Schöffski, Patrick , Mehren, Margaret von , Kang, Yoon‐Koo , Razak, Albiruni Abdul , Attia, Steven , Cesne, Axel Le , Su, Ying , Meade, Julie, Wang, Tao , Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , von Mehren, Margaret , Kang, Yoon-Koo , Trent, Jonathan , Attia, Steven , Le Cesne, Axel , Su, Ying , Ruiz-Soto, Rodrigo , Heinrich, Michael C , Blay, Jean-Yves , Jones, Robin L , Gelderblom, Hans , George, Suzanne , Bauer, Sebastian , Zalcberg, John , Trent, Jonathan C. , Heinrich, Michael C.

Mayo Clinic

Journal of Clinical Oncology | August 10, 2022 | Volume: 40 | Issue: 34 | Pages: 3918-3928

10.1200/jco.22.00294 | PMID 35947817 Get It

PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously treated with imatinib (INTRIGUE, ClinicalTrials.gov identifier: NCT03673501 ). PATIENTS AND METHODS Random assignment was 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off) and stratified by KIT/ platelet-derived growth factor α mutation and imatinib intolerance. The primary end point was progression-free survival (PFS) by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included objective response rate by independent radiologic review, safety, and patient-reported outcome measures. RESULTS Overall, 453 patients were randomly assigned to ripretinib (intention-to-treat [ITT], n = 226; KIT exon 11 ITT, n = 163) or sunitinib (ITT, n = 227; KIT exon 11 ITT, n = 164). Median PFS for ripretinib and sunitinib ( KIT exon 11 ITT) was 8.3 and 7.0 months, respectively (hazard ratio, 0.88; 95% CI, 0.66 to 1.16; P = .36); median PFS (ITT) was 8.0 and 8.3 months, respectively (hazard ratio, 1.05; 95% CI, 0.82 to 1.33; nominal P = .72). Neither was statistically significant. Objective response rate was higher for ripretinib versus sunitinib in the KIT exon 11 ITT population (23.9% v 14.6%, nominal P = .03). Ripretinib was associated with a more favorable safety profile, fewer grade 3/4 treatment-emergent adverse events (41.3% v 65.6%, nominal P < .0001), and better scores on patient-reported outcome measures of tolerability. CONCLUSION Ripretinib was not superior to sunitinib in terms of PFS. However, meaningful clinical activity, fewer grade 3/4 treatment-emergent adverse events, and improved tolerability were observed with ripretinib.
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Flaig, Thomas W. , Abern, Michael, Agarwal, Neeraj , Bangs, Rick , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chan, Kevin , Friedlander, Terence W. , Greenberg, Richard E. , Guru, Khurshid A. , Herr, Harry W., Hoffman‐Censits, Jean , Kishan, Amar U. , Kundu, Shilajit , Lele, Subodh M. , Mamtani, Ronac , Margulis, Vitaly , Michalski, Jeff M., Montgomery, Jeffrey S., Nandagopal, Lakshminarayanan , Pagliaro, Lance C. , Patterson, Anthony, Pohar, Kamal S. , Preston, Mark A. , Sexton, Wade J. , Tollefson, Matthew K. , Wright, Jonathan L. , Dwyer, Mary A., Cassara, Carly J., Gurski, Lisa A., Tollefson, Matthew, Spiess, Philippe E. , Agarwal, Neeraj , Chang, Sam S. , Mian, Omar Y. , Parikh, Mamta , Plimack, Elizabeth R. , Richards, Kyle A. , Siefker-Radtke, Arlene Odelia , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 10, 2022 | Volume: 20 | Issue: 8 | Pages: 866-878

10.6004/jnccn.2022.0041 | PMID 35948037 Get It

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non–muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non–muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody–drug conjugates for metastatic bladder cancer.
If Aristotle Were a Surgeon
Cook, David A. , D’Angelo, Anne-Lise D. , D'Angelo, Jonathan D, D'Angelo, Anne-Lise D, D’Angelo, Jonathan D.

Mayo Clinic

Annals of Surgery | August 9, 2022 | Volume: 277 | Issue: 3 | Pages: e489-e490

10.1097/sla.0000000000005674 | PMID 35943200 Get It

LOCL-03 INTRATUMORAL DELIVERY OF CONDITIONALLY REPLICATIVE HUMAN ADENOVIRUS 657 EXPRESSING THE IMMUNE CO-STIMULATOR CD40L (CRAD657-CD40L) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA
Khatua, Soumen , Thompson, Jill , Yerovi, Maria Chiriboga , Schartz, Jonathan, Wongthida, Phonphimon , Hopps, Sidney, Barry, Mary, Vile, Richard G. , Díaz, Rosa María, Webb, Mason , Daniels, David J. , Barry, Michael A.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i12-i12

10.1093/noajnl/vdac078.045 Get It

Abstract INTRODUCTION Malignancies of the central nervous system (CNS) have had largely unchanged survival outcomes despite decades of research. Recently, viral-based therapeutics have shown some benefit for patients with CNS malignancies in early clinical trials. Adenovirus has been demonstrated as safe and is currently being examined in several phase I and II clinical trials. We recently demonstrated that adenovirus expressing CD40L is effective in enhancing survival in murine models of diffuse midline glioma. Therefore, to enhance the tumor specificity of this virotherapy, we hypothesized that by using a novel conditionally replicative adenovirus expressing CD40L, CRAd657-CD40L, we would maintain this survival benefit in multiple murine models for high grade glioma while decreasing off-target toxicity. METHODS We examined the utility of conditionally replicative adenovirus expressing CD40L in both in vitro and in vivo studies. Human cell lines from diffuse intrinsic pontine glioma (DIPG) and glioblastoma were used to confirm infectivity and CD40L expression, and syngeneic murine models of glioma were evaluated for toxicity and survival following intratumoral injection of a conditionally replicative adenoviral vector. RESULTS CRAd657-CD40L generated strong expression of CD40L in human in vitro DIPG XIII and U251 cell lines and induced MHCII expression on CD11c+ DC’s in U251/DC co-culture. Further, in syngeneic murine models of glioma, conditionally replicative adenoviral treatment significantly reduced toxicity while retaining survival efficacy. CONCLUSIONS Given these promising results as well as the critical need for novel therapeutics in CNS malignancies, we are now progressing to human trials targeting pediatric HGG, an unmet need in pediatric neuro-oncology. This would be the first-in-human study using CRAd-657-CD40L in pediatric HGG. In this Phase 1 clinical trial, we hypothesize that intratumoral injection of CRAd657-CD40L will cause selective expression of CD40L, increased infiltration of immune cells into the tumor, and safely enhance tumor clearance.
LOCL-07 LOCO-REGIONAL INFUSION OF GB-13 (IL13.E13K-PE4E) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT HIGH-GRADE GLIOMA
Khatua, Soumen , Campian, Jian , Schwartz, Jonathan , Schrecengost, Randy S., Rechberger, Julian S. , Sarkaria, Jann N. , Daniels, David J.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i13-i13

10.1093/noajnl/vdac078.049 Get It

Abstract INTRODUCTION High grade gliomas (HGG) are devastating diseases with largely unchanged survival outcomes despite decades of research. Recent studies suggest the interleukin 13 receptor subunit alpha 2 (IL-13Rα2) is selectively upregulated in up to 80% of HGG, including glioblastoma (GBM) and diffuse midline gliomas (DMG) harboring H3K27 alterations. Immunotoxins targeting IL-13Rα2 have been demonstrated as safe and have shown some benefit for patients with HGG in previous phase I/II and III clinical trials. We hypothesized that by using GB-13 (IL13.E13K-PE4E), a novel peptide-toxin that binds IL-13Rα2 with high specificity and possesses a Pseudomonas exotoxin moiety, we would enhance the anti-tumor effects of this immunotherapy for HGG in vitro and in vivo while decreasing off-target toxicity. METHODS We examined the pharmacological effects of GB-13 in multiple patient-derived cell lines and rodent models of HGG. GBM and DMG lines were used to confirm IL-13Rα2 expression and sensitivity towards GB-13. Tumor naïve rats were evaluated for toxicity, and orthotopic PDX mice were used to monitor tumor size and survival following loco-regional infusion of GB-13. RESULTS GB-13 induced a potent cytotoxic response strongly predicated on IL-13Rα2 expression in vitro. No treatment-related adverse effects were noted after 7-day continuous intracranial infusion of GB-13 in tumor naïve rats. Further, in IL-13Rα2-upregulated orthotopic PDX mice, direct intratumoral administration of GB-13 via convection-enhanced delivery abrogated tumor growth and prolonged survival. CONCLUSIONS Given these promising results as well as the critical need for novel therapies in CNS malignancies, we are progressing to human trials using GB-13 targeting recurrent HGG. Ongoing safety studies in tumor-bearing animals will be able to define dose levels for the initial adult study-arm and the following pediatric study-arm. In this Phase 1 clinical trial, we hypothesize that loco-regional infusion of GB-13 will safely enhance tumor clearance by causing selective killing of IL-13Rα2-upregulated HGG cells.